Literature DB >> 19662652

Cytotoxic effects of antipsychotic drugs implicate cholesterol homeostasis as a novel chemotherapeutic target.

Erik D Wiklund1, Vibeke S Catts, Stanley V Catts, Teng Fong Ng, Noel J Whitaker, Andrew J Brown, Louise H Lutze-Mann.   

Abstract

The reported reduction in cancer risk in those suffering from schizophrenia may be because antipsychotic medications have antineoplastic effects. In this study, 6 antipsychotic agents with a range of structural and pharmacological properties (reserpine, chlorpromazine, haloperidol, pimozide, risperidone and olanzapine), were screened for their effect on the viability of cell lines derived from lymphoblastoma, neuroblastoma, non-small cell lung cancer and breast adenocarcinoma. We aimed to determine if antipsychotic drugs in general possess cancer-specific cytotoxic potential, and whether it can be attributed to a common mode of action. With the exception of risperidone, all drugs tested displayed selective inhibition of the viability of cancer cell lines compared with normal cells. Using Affymetrix expression microarrays and quantitative real-time polymerase chain reaction, we found that for the antipsychotic drugs, olanzapine and pimozide, cytotoxicity appeared to be mediated via effects on cholesterol homeostasis. The role of cholesterol metabolism in the selective cytotoxicity of these drugs was supported by demonstration of their increased lethality when coadministered with a cholesterol synthesis inhibitor, mevastatin. Also, pimozide and olanzapine showed accelerating cytotoxic effects from 12 to 48 hr in time course studies, mirroring the time-dependent onset of cytotoxicity induced by the amphiphile, U18666A. On the basis of these results, we concluded that the Class II cationic amphiphilic properties of antipsychotic drugs contribute to their cytotoxic effects by acting on cholesterol homeostasis and altering the biophysical properties of cellular membranes, and that drugs affecting membrane-related cholesterol pathways warrant further investigation as potential augmentors of standard cancer chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19662652     DOI: 10.1002/ijc.24813

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  36 in total

1.  Experimental analysis and modelling of in vitro HUVECs proliferation in the presence of various types of drugs.

Authors:  L Mancuso; M Scanu; M Pisu; A Concas; G Cao
Journal:  Cell Prolif       Date:  2010-12       Impact factor: 6.831

2.  The Effect of Small Molecules on Sterol Homeostasis: Measuring 7-Dehydrocholesterol in Dhcr7-Deficient Neuro2a Cells and Human Fibroblasts.

Authors:  Zeljka Korade; Hye-Young H Kim; Keri A Tallman; Wei Liu; Katalin Koczok; Istvan Balogh; Libin Xu; Karoly Mirnics; Ned A Porter
Journal:  J Med Chem       Date:  2016-01-29       Impact factor: 7.446

3.  Aberrantly high expression of the CUB and zona pellucida-like domain-containing protein 1 (CUZD1) in mammary epithelium leads to breast tumorigenesis.

Authors:  Janelle Mapes; Lavanya Anandan; Quanxi Li; Alison Neff; Charles V Clevenger; Indrani C Bagchi; Milan K Bagchi
Journal:  J Biol Chem       Date:  2018-01-10       Impact factor: 5.157

4.  Repurposing antipsychotics as glioblastoma therapeutics: Potentials and challenges.

Authors:  Jin-Ku Lee; DO-Hyun Nam; Jeongwu Lee
Journal:  Oncol Lett       Date:  2016-01-07       Impact factor: 2.967

5.  The novel anticancer agent JNJ-26854165 induces cell death through inhibition of cholesterol transport and degradation of ABCA1.

Authors:  Richard J Jones; Dongmin Gu; Chad C Bjorklund; Isere Kuiatse; Alan T Remaley; Tarig Bashir; Veronique Vreys; Robert Z Orlowski
Journal:  J Pharmacol Exp Ther       Date:  2013-07-02       Impact factor: 4.030

6.  Identification of antipsychotic drug fluspirilene as a potential p53-MDM2 inhibitor: a combined computational and experimental study.

Authors:  Sachin P Patil; Michael F Pacitti; Kevin S Gilroy; John C Ruggiero; Jonathan D Griffin; Joseph J Butera; Joseph M Notarfrancesco; Shawn Tran; John W Stoddart
Journal:  J Comput Aided Mol Des       Date:  2014-11-07       Impact factor: 3.686

7.  We contain multitudes: the protean face of retinoblastoma.

Authors:  Seth Blackshaw
Journal:  Cancer Cell       Date:  2011-08-16       Impact factor: 31.743

Review 8.  Learning the molecular mechanisms of the reprogramming factors: let's start from microRNAs.

Authors:  Chao-Shun Yang; Tariq M Rana
Journal:  Mol Biosyst       Date:  2012-10-05

Review 9.  Opposite Interplay Between the Canonical WNT/β-Catenin Pathway and PPAR Gamma: A Potential Therapeutic Target in Gliomas.

Authors:  Alexandre Vallée; Yves Lecarpentier; Rémy Guillevin; Jean-Noël Vallée
Journal:  Neurosci Bull       Date:  2018-03-26       Impact factor: 5.203

10.  Glioblastoma radiosensitization by pimozide.

Authors:  Barbara H Rath; Kevin Camphausen; Philip J Tofilon
Journal:  Transl Cancer Res       Date:  2016-11       Impact factor: 1.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.